



Vormatrigine Exhibits a Favorable Drug-Drug Interaction Profile Supporting Broad Combination Use with Antiseizure Medications

Archis Patel, Noam Epstein, Karl Hansen, Silvana Frizzo, Henry Jacotin, Dharit Patel, Hong Sun, Steven Petrou, Marcio Souza
Praxis Precision Medicines, Boston, MA, USA

BACKGROUND

- Vormatrigine (PRAX-628), a functional state modulator that selectively targets the hyperexcitable state of CNS sodium channels, is currently in development for adult focal onset seizures and generalized epilepsy, with preclinical and clinical data to date pointing to a differentiated precision antiseizure medication (ASM) profile.
- Given that polytherapy is common in epilepsy management, understanding the drug-drug interaction (DDI) potential of vormatrigine is critical.
- **A combination of preclinical studies and dedicated clinical DDI trials was undertaken to evaluate vormatrigine’s liability for metabolic clearance drug interactions, with the goal of supporting its utilization alongside a broad spectrum of ASMs.**

METHODS


- An integrated nonclinical and clinical approach was used to assess the DDI profile of vormatrigine.

Preclinical Evaluations

- Preclinical evaluations included *in vitro* studies of cytochrome P450 (CYP450) and uridine diphosphate glucuronosyltransferase (UGT) metabolism, transporter interaction profiling, and hepatocyte induction assays.
- Key enzymes assessed included CYP1A2, 2C19, 3A4, and UGT isoforms, along with major efflux and uptake transporters.

Clinical Evaluations

- A Phase 1 PRAX-628-102 study in healthy adults evaluated how vormatrigine exposure is affected by co-administration with commonly used metabolic inhibitors:
 - Fluvoxamine (CYP1A2/2C19 inhibitor)
 - Itraconazole (CYP3A4 inhibitor)
 - Probenecid (non-selective UGT inhibitor)
- The study also assessed the effects of cigarette smoking, a known inducer of CYP1A2.
- Vormatrigine PK was evaluated using non-compartmental analysis with linear mixed-effects modeling.



CYP=cytochrome P450; UGT=uridine diphosphate-glucuronosyltransferase

*Probe Drug Assignment

- Fluvoxamine (Strong inhibitor of CYP1A2 and CYP2C19)
- Itraconazole (Strong CYP3A inhibitor)
- Probenecid (Non-selective UGT inhibitor)

Fluvoxamine and itraconazole groups had 2 cohorts each

- Cohort A = Non-smokers
- Cohort B = Smokers

PRAX-628-102 DDI Evaluation Schema

PARTICIPANT DEMOGRAPHICS & BASELINE CHARACTERISTICS

- A total of 120 participants were enrolled, of which 43 were included in safety and PK analysis sets.
- No clinically significant differences regarding medical and surgical history or prior medication use.
- Drug screen results were negative for all participants at screening/admission, except cotinine positive for smokers.
- Serology parameters were negative at screening for all participants.
- Pregnancy test results were negative at screening for all females.

Summary of Demographics by Probe Group and Overall (Safety Set)

		Fluvoxamine (N=17)	Itraconazole (N=10)	Probenecid (N=16)	All (N=43)
Age (years)	Mean (SD)	36.0 (14.12)	38.4 (11.46)	35.5 (10.14)	36.4 (11.92)
Sex, n (%)	Male	14 (82.4)	6 (60.0)	11 (68.8)	31 (72.1)
	Female	3 (17.6)	4 (40.0)	5 (31.3)	12 (27.9)
Ethnicity, n (%)	Hispanic or Latino	2 (11.8)	0 (0)	1 (6.3)	3 (7.0)
	Not Hispanic or Latino	15 (88.2)	10 (100)	15 (93.8)	40 (93.0)
Race, n (%)	Asian	0 (0)	0 (0)	1 (6.3)	1 (2.3)
	White	17 (100)	9 (90.0)	14 (87.5)	40 (93.0)
	White + Asian	0 (0)	1 (10.0)	1 (6.3)	2 (4.7)
Height (cm)	Mean (SD)	180.8 (5.95)	171.9 (10.42)	176.1 (9.26)	177.0 (8.92)
Weight (kg)	Mean (SD)	77.48 (13.21)	73.90 (9.96)	75.23 (15.64)	75.81 (13.31)
BMI (kg/m ²)	Mean (SD)	23.66 (3.58)	25.00 (2.73)	24.09 (3.28)	24.13 (3.25)

MINIMAL DDI RISK ON COMBINED PRECLINICAL & CLINICAL EVALUATION

- Preclinically, vormatrigine showed:
 - Low metabolic turnover in human hepatocytes.
 - Minor involvement of CYPs and UGTs in its clearance.
 - Weak inhibition of CYP2D6 and intestinal CYP3A at supratherapeutic concentrations.
 - Minimal transporter interaction risk; some *in vitro* BCRP and MDR1 inhibition not expected to be clinically relevant.
- Clinically, coadministration with:
 - Fluvoxamine increased vormatrigine exposure by about 17% on C_{max} and by 30% based on AUC, suggesting that CYP1A2 is involved in vormatrigine metabolism and that strong CYP1A2 inhibitors have a weak effect on vormatrigine exposure.
 - The effect of fluvoxamine on vormatrigine exposure was lower in smokers than in non-smokers.
 - Itraconazole had no significant impact on AUC, indicating that CYP3A4 has no major role in vormatrigine clearance. A reduction in C_{max} was observed, consistent with a transient effect on the rate rather than the extent of absorption; most likely attributable to interaction in the GI tract with components in the itraconazole dosing solution (such as cyclodextrin), and is not expected to be clinically meaningful.
 - Probenecid did not affect plasma vormatrigine exposure, suggesting that vormatrigine is not significantly metabolized by UGTs.

Statistical Analysis of the Drug-Drug Interaction Between Vormatrigine and Probe Drugs

PK Parameter (Unit)	Ratio of GLSM (Test/Reference)	90% CIs for GLSM Ratio	
		Lower	Upper
Fluvoxamine (N=17)			
C _{max} (ng/mL)	1.17	1.044	1.304
AUC _{0-inf} (h×ng/mL)	1.22	0.996	1.498
Itraconazole (N=10)			
C _{max} (ng/mL)	0.61	0.518	0.718
AUC _{0-inf} (h×ng/mL)	1.06	0.913	1.226
Probenecid (N=16)			
C _{max} (ng/mL)	0.79	0.724	0.865
AUC _{0-inf} (h×ng/mL)	0.89	0.851	0.926

CI = Confidence interval; GLSM= Geometric least squares mean; N= Number of participants

SAFETY SUMMARY

- A single oral dose of 10 mg vormatrigine with or without concomitant treatment with 50 mg/100 mg fluvoxamine, 200 mg itraconazole, or 1000 mg probenecid was well tolerated in healthy participants.
- No deaths, SAEs, AESIs, or other clinically meaningful AEs occurred during the trial. There were 2 participants who discontinued the trial due to AEs; 1 in fluvoxamine cohort and 1 in probenecid cohort. Both AEs, vomiting and rash, were not related to the study drug.
- There were no clinically significant findings identified for clinical laboratory, vital signs, 12-lead ECGs, physical examinations, or C-SSRS.

CONCLUSIONS

- Vormatrigine exhibits a favorable DDI profile, supported by both preclinical mechanistic studies and human PK data.
- Given no clinically meaningful interactions were observed with major CYP and UGT pathways, vormatrigine is well-suited for use in multi-drug epilepsy regimens, including a broad array of ASMs without the need for dose adjustments.
- These findings point to vormatrigine’s potential as a best-in-class sodium channel modulator and continue to inform the ENERGY program for epilepsy.



Topline Results
Platform Session 1,
Adult Epileptology 1,
Talk 6



Topline Results
Platform Session 9,
Drug Therapy and Clinical Trials,
Talk 4



Study Design – Restarting 4Q26
Poster P0346

REFERENCES

- Kahlig et al AAN 2023
- Bialer et al 2024 *Epilepsia*
- Anderson et al AES 2023
- Anderson et al AES 2024
- Anderson et al IEC 2025
- Hansen et al IEC 2023
- Hansen et al EEC 2024
- Hansen et al IEC 2025
- Bialer et al 2026 *Epilepsia*

Acknowledgments We thank the participants and their families, as well as our collaborators for their contributions to this work.

Funding All work was funded by Praxis Precision Medicines. Medical writing and editorial assistance were provided by Lillian G. Matthews and Laila S. Almassri in accordance with Good Publication Practice (GPP).

Disclosures All authors are current or former employees/consultants of Praxis Precision Medicines and may be Praxis shareholders.

@PraxisMedicines

Praxis Precision Medicines

Praxismedicines.com

clinicaltrials@praxismedicines.com



Presented at:
European Epilepsy
Congress
5-9 Sept 2026
Athens, Greece

